Table 1—

Baseline characteristics of subjects in the intervention and control groups

CharacteristicsIntervention groupControl group
n4035
Sex (n)
 Men79
 Women3326
Age (years)60 ± 1057 ± 9
Weight (kg)72.4 ± 14.671.9 ± 12.4
BMI (kg/m2)30.1 ± 5.129.0 ± 4.6
Fasting plasma glucose (mg/dl)186 ± 103171 ± 85
Glycosylated hemoglobin (%)8.6 ± 3.78.6 ± 3.9
Serum lipids (mg/dl)
 Total cholesterol247 ± 52227 ± 47
 HDL cholesterol45 ± 1242 ± 10
 LDL cholesterol*156 ± 47144 ± 36
 Triglycerides288 ± 244237 ± 215
Blood pressure (mmHg)
 Systolic138 ± 19134 ± 17
 Diastolic84 ± 1082 ± 10
Use of hypoglycemic medications (%)
 All classes8686
 Sulfonylureas6257
 Metformin3543
 Insulin3226
Use of antihypertensive medications (%)
 All classes5143
 ACE inhibitors2214
 β-adrenergic blockers2217
 Calcium channel blockers1414
 Other2211
Use of lipid-lowering medications (%)
 All classes3318
 Gemfibrozil119
 Lovastatin229
  • Data are means ± SD unless otherwise indicated. LDL cholesterol = total cholesterol − (triglycerides/5 + HDL cholesterol). LDL cholesterol values were only calculated when triglycerides were < 400 mg/dl. For this reason, n = 67 for LDL cholesterol (intervention groups, n = 35; control groups, n = 32).

  • Baseline medications were established via chart review and physician consultation. Because three charts had incomplete or missing data, n = 72 (intervention groups, n = 37; control groups, n = 35). Numbers indicate percentages of all subjects taking the given class of medication within a treatment stratum.